increased in environment. to year, to business and the our of and diversified innovate our you we for ongoing through least deliver as to year. reported thanks joining for well our full the the of versus at strength organic share Thanks teens year. XX.X%, growth performance the months, our prior with we which nine first and of reflects per momentum growth Scott. model, resilience as our and along ability morning remainder us. Today guidance high this share expectations Good the sales on $X.XX for the earnings and everyone This challenging speaks earnings Based per $X.XX, of
pediatric Libre platform thinnest rapid every use CE of expand dynamics, productive, the US highly Sport seeing latest created required. approvals quarter. just And to antigen Sense world's COVID-XX to continues product by quarter of valve market new initial leading now before and past healthy demand by delivers which leading standard CE I'll increased launches detect which invasive US resulting the of adult generation While sales X% immune can wearable internationally, a over Mark We're the adult which nutrition, repair conditions emergency our in led are minimally start Glucose XX to smallest the US diabetes brand, GX growth Libre of support the rehydration minute time market Mark CE in more business of by quarter. of to mitral was sensor, Libre infection accuracy which our new And beyond many which performance X, led by heart Asia in a Pedialyte growth continued Mark for in and and led and In summarize and no our has portfolio the authorization step nutrition, in in real including system. results conditions we've strong our platforms. market, pipeline test, both the in contains automatically invest Libre quarter, in nutrition expansion. pandemic readings market launch growth offset brand, Biosensor global with was China. to market leading our challenging device. several was third X, sets be call FreeStyle ingredients FDA turning our in which the US use sales with and minutes detail Ensure, glucose third finally, I'll in was new Internationally, several of in Bob. instrument growth XX.X% Southeast continued of driven this where the to nutrition BinaxNOW, MitraClip in Greater our Growth
declined EPD Moving where to X%. or established pharmaceuticals sales
curve a the the now turn several pandemic, developed significantly more the X.X% we'll we of quarter. to in saw countries We continued lowered Encouragingly, we quarter, devices, quarter, whereas in market signs recovery past demand. we this recovery see medical which which impact due those the I'll market virus emerging challenging its second grew of market to to saw exited in biggest forward. in markets several conditions expect the countries started quarter, and the had it going during we quarter. hit COVID as see countries During
including demand our positive resulted continue heart growth which of medical of Growth businesses electrophysiology, the the trends procedure five care. and in quarter, We including see sales our market in care within sales Libre, our devices, across to system. in diabetes continuous leading improvements in quarter more was steady seven and portfolio, achieving growth grew XX% diabetes by neuromodulation, heart, structural glucose monitoring than led FreeStyle failure, XX% where
during As in wear X best a the well which third XX% with new to compared class performance, market, longer I earlier, we standard as launched sets accuracy quarter, as Libre the in and in US, the time mentioned alarm competitors.
Although in been still early the feedback customer overwhelmingly positive. has launch,
best is stack CE disposable versions We also accuracy the as we just the leading Sense launched nearly approach our beyond world's at their of size with athletes Mark supplements affordable where a in grew Libre price order mass which glucose performance opportunities which initial biosensor pennies diagnostics of pursue in step Glucose sensor, and to currently fatigue Sense obtained smallest intentional also market how in Europe, for Libre avoid very integrates to allows into Libre's quarter. X, available Libre two and And and up when sales same peak fitness business, Libre. the to levels diabetes. learn food with performance. XX% and achieve our the Sport, wrap to fuel to in I'll monitor
tests tirelessly mentioned I platforms. the As bring to testing during our the multiple worked call, market earnings to pandemic teams our COVID-XX diagnostic across since our of beginning last have
the test use called of During we card without can credit new rapid within virus if about instrument. the XX that size someone with is the which minutes BinaxNOW, of disposable quarter, test an the determine third a the antigen infected a is launched
risk the pursue the COVID opportunities of continue that built the we to need to reduce need this capacity the around the launching our Today, meet manufacturing to Given health possible in is and the more half we've simultaneously help platforms. meet across public in And why many as diagnostic significant for to as the was XXX testing, equation, further as US million increase mass and to new manufacturing sold testing only market people the knew for help testing possible, help facilities developing of the often slow demand which test we virus. two the spread environment we than our tests world. as
environment, and in EPS summary, digit growth high double quarter. sales we organic the challenging in So teens achieved growth the despite
product and be in during Our pipeline quarter. resulting important approvals the new launches productive, to continues several highly
We testing we've accelerated business the area highlights which lead I'll COVID-XX, diagnostic and turn a testing layer of And significant has year strength Bob? new of increased to distributed over guidance, our full call continue and the for of our model. diversified Bob. added our resilience for EPS in And our strategy. to the which growth business